The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: A dialogue and debate

Current Hematologic Malignancy Reports

Volumn 6, Issue 2, 2011, Pages 136-144

  Steensma, David P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Classical dialogue; Clinical controversy; Deferasirox; Deferoxamine; Ferritin; Iron chelation therapy; Iron overload; Labile plasma iron; magnetic resonance imaging; Myelodysplastic syndromes (MDS); Practice guidelines; T2; Transfusional hemosiderosis

Indexed keywords

FERRITIN; TRANSFERRIN;

COMORBIDITY; FERRITIN BLOOD LEVEL; HEALTH CARE COST; HUMAN; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; REVIEW; STEM CELL TRANSPLANTATION; THALASSEMIA; TREATMENT OUTCOME;

CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; RISK ASSESSMENT; RISK FACTORS;

EID: 79957510305     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0084-z     Document Type: Review

References (49)

1. DP Steensma 2009 Myelodysplasia paranoia: iron as the new radon Leuk Res 33 1158 63 19036443 10.1016/j.leukres.2008.10.017 1:CAS:528:DC%2BD1MXnvVaksbk%3D
2. A Tefferi RM Stone 2009 Iron chelation therapy in myelodysplastic syndrome-Cui bono? Leukemia 23 1373 19672273 10.1038/leu.2009.39 1:STN:280:DC%2BD1MrkvFKjtw%3D%3D
3. HA Leitch 2011 Controversies surrounding iron chelation therapy for MDS Blood Rev 25 17 31 21030120 10.1016/j.blre.2010.09.003 1:CAS:528: DC%2BC3cXhsFCqsL7M
4. DP Steensma 2011 The role of iron chelation therapy for patients with myelodysplastic syndromes J Natl Compr Canc Netw 9 65 75 21233245
5. L Malcovati 2007 Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes Leuk Res 31 Suppl 3 S2 6 18037415 10.1016/S0145-2126(07)70459-9 1:CAS:528:DC%2BD2sXhtlGhsrvM (Pubitemid 350137500)
6. M Cazzola L Malcovati 2005 Myelodysplastic syndromes-coping with ineffective hematopoiesis N Engl J Med 352 536 8 15703418 10.1056/NEJMp048266 1:CAS:528:DC%2BD2MXhtFemsr0%3D (Pubitemid 40204666)
7. EJ Lesnefsky 1994 Tissue iron overload and mechanisms of iron-catalyzed oxidative injury Adv Exp Med Biol 366 129 46 7771248 1:CAS:528: DyaK2MXpsl2gu7s%3D
8. DP Steensma A Tefferi 2007 Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc 82 958 66 17673065 10.4065/82.8.958 1:CAS:528:DC%2BD2sXpslertL4%3D (Pubitemid 47206371)
9. Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008:166-75.
10. L Malcovati MG Porta C Pascutto, et al. 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594 603 16186598 10.1200/JCO.2005.01.7038 (Pubitemid 46291823)
11. M Takatoku T Uchiyama S Okamoto, et al. 2007 Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality Eur J Haematol 78 487 94 17391310 10.1111/j.1600-0609.2007.00842.x 1:CAS:528:DC%2BD2sXotV2gsbc%3D (Pubitemid 46753591)
12. AF Remacha B Arrizabalaga C Del Canizo G Sanz A Villegas 2010 Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements Ann Hematol 89 147 54 19690857 10.1007/s00277-009-0794-7 1:CAS:528:DC%2BC3cXjt1ylsQ%3D%3D
13. P Greenberg C Cox MM LeBeau, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 88 9058730 1:CAS:528:DyaK2sXhvVars70%3D (Pubitemid 27132124)
14. TG DeLoughery 2009 Iron: The fifth horseman of the apocalypse? Am J Hematol 84 263 4 19358299 10.1002/ajh.21413
15. CE Chee DP Steensma W Wu CA Hanson A Tefferi 2008 Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts Am J Hematol 83 611 3 18442062 10.1002/ajh.21192 1:CAS:528:DC%2BD1cXhtVGls7jN
16. MM Patnaik TL Lasho CM Finke, et al. 2010 WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations Leukemia 24 1283 9 20485371 10.1038/leu.2010.105 1:CAS:528:DC%2BC3cXovFKmsL4%3D This paper, taken together with reference [15], suggests that the relationship between serum ferritin and risk of death in MDS is not simple
17. A Tefferi RA Mesa A Pardanani, et al. 2009 Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not Am J Hematol 84 265 7 19396855 10.1002/ajh.21391 1:CAS:528:DC%2BD1MXmtFelsrg%3D
18. M Cazzola G Barosi PG Gobbi R Invernizzi A Riccardi E Ascari 1988 Natural history of idiopathic refractory sideroblastic anemia Blood 71 305 12 3337899 1:STN:280:DyaL1c7gvVWgtQ%3D%3D (Pubitemid 18089515)
19. V Pullarkat 2009 Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114 5251 5 19710499 10.1182/blood-2009-07-234062 1:CAS:528:DC%2BC3cXislWktw%3D%3D This is a thoughtful discussion of the possibility that iron chelation may be important not because it removes large amounts of iron from the body, but because chelation reduces the serum and cellular levels of labile, redox-active iron species
20. A Sane S Manzi J Perfect AJ Herzberg JO Moore 1989 Deferoxamine treatment as a risk factor for zygomycete infection J Infect Dis 159 151 2 2909637 10.1093/infdis/159.1.151 1:STN:280:DyaL1M%2FotVentg%3D%3D (Pubitemid 19022014)
21. P Armand HT Kim CS Cutler, et al. 2007 Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 4586 8 17234738 10.1182/blood-2006-10-054924 1:CAS:528:DC%2BD2sXls1amtrY%3D (Pubitemid 46743431)
22. A Mahindra B Bolwell R Sobecks, et al. 2007 Prognostic impact of elevated pretransplant serum ferritin in allogeneic hematopoietic stem cell transplantation [abstract] Blood (ASH Annual Meeting Extracts) 110 1109
23. V Pullarkat S Blanchard B Tegtmeier, et al. 2008 Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation Bone Marrow Transplant 42 799 805 18762767 10.1038/bmt.2008.262 1:CAS:528: DC%2BD1MXhtVGktQ%3D%3D
24. U Platzbecker G Ehninger M Bornhauser 2007 Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation Blood 110 3083 17916753 10.1182/blood-2007-05-089839 1:CAS:528:DC%2BD2sXht1Smu7zL author reply -4 (Pubitemid 350006967)
25. D Metcalf 1985 The granulocyte-macrophage colony-stimulating factors Science (New York, NY) 229 16 22 10.1126/science.2990035 1:CAS:528: DyaL2MXksVyhtbs%3D
26. MD Cappellini J Porter A El-Beshlawy, et al. 2010 Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias Haematologica 95 557 66 19951979 10.3324/haematol.2009.014696 1:CAS:528:DC%2BC3cXhtlWjs7fP This is the largest prospective study to date of deferasirox in transfusion-dependent anemias, including MDS
27. A List M Baer D Steensma, et al. 2007 Deferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS) [abstract] Blood (ASH Annual Meeting Abstracts) 110 1470
28. G Sanz B Nomdedeu E Such, et al. 2008 Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract] Blood (ASH Annual Meeting Abstracts) 112 640
29. S Nagata M Tsuchiya S Asano, et al. 1986 Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor Nature 319 415 8 3484805 10.1038/319415a0 1:CAS:528:DyaL28Xht1Ciu70%3D (Pubitemid 16163903)
30. J Chacko DJ Pennell MA Tanner, et al. 2007 Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions Br J Haematol 138 587 93 17610536 10.1111/j.1365-2141.2007.06695.x 1:CAS:528:DC%2BD2sXhtVKgsr7P (Pubitemid 47206717)
31. E Konen H Ghoti O Goitein, et al. 2007 No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique Am J Hematol 82 1013 6 17654681 10.1002/ajh.20980 (Pubitemid 350004394)
32. AA Di Tucci G Matta S Deplano, et al. 2008 Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias Haematologica 93 1385 8 18603557 10.3324/haematol.12759
33. L Pascal OB Rauzy S Brechignac, et al. 2010 Highly transfused MDS patients often have cardiac iron overload, as shown by MRI assessment [abstract] Blood (ASH Annual Meeting Extracts) 116 2906
34. GM Brittenham PM Griffith AW Nienhuis, et al. 1994 Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major N Engl J Med 331 567 73 8047080 10.1056/NEJM199409013310902 1:STN:280:DyaK2czit1yntQ%3D%3D (Pubitemid 24265698)
35. NF Olivieri DG Nathan JH MacMillan, et al. 1994 Survival in medically treated patients with homozygous beta-thalassemia N Engl J Med 331 574 8 8047081 10.1056/NEJM199409013310903 1:STN:280:DyaK2czit1ynug%3D%3D (Pubitemid 24265699)
36. T Tanno NV Bhanu PA Oneal, et al. 2007 High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nat Med 13 1096 101 17721544 10.1038/nm1629 1:CAS:528:DC%2BD2sXhtVSgtrvK (Pubitemid 47517510)
37. H Ghoti J Amer A Winder E Rachmilewitz E Fibach 2007 Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome Eur J Haematol 79 463 7 17976187 10.1111/j.1600-0609. 2007.00972.x (Pubitemid 350126678)
38. BD Cheson PL Greenberg JM Bennett, et al. 2006 Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood 108 419 25 16609072 10.1182/blood-2005-10-4149 1:CAS:528:DC%2BD28XntFehtrk%3D (Pubitemid 44061337)
39. N Gattermann C Finelli MG Della Porta, et al. 2010 Hematologic responses in myelodysplastic syndromes (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using International Working Group (IWG) 2006 Criteria [abstract] Blood (ASH Annual Meeting Extracts) 116 2912
40. HA Leitch DHC Wong CS Leger, et al. 2007 Improved leukemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis Blood (ASH Annual Meeting Abstracts) 110 1469
41. C Rose S Brechignac D Vassilief, et al. 2010 Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies) Leuk Res 34 864 70 20129667 10.1016/j.leukres.2009.12.004 1:CAS:528:DC%2BC3cXmsVSls7k%3D
42. AF List MR Baer DP Steensma, et al. 2009 Two-year analysis of efficacy and safety of deferasirox (Exjade®) treatment in myelodysplastic syndrome patients enrolled in the US03 Study [abstract] Blood (ASH Annual Meeting Extracts) 116 3829
43. PD Jensen L Heickendorff B Pedersen, et al. 1996 The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload Br J Haematol 94 288 99 8759889 10.1046/j.1365-2141.1996.d01-1795.x 1:STN:280:DyaK28zis1agsw%3D%3D (Pubitemid 26247987)
44. GJ Kontoghiorghes 2008 Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox Hemoglobin 32 1 15 18274978 10.1080/03630260701726533 1:CAS:528:DC%2BD1cXhvFWiur0%3D (Pubitemid 351264512)
45. E Messa S Carturan C Maffe, et al. 2010 Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging Haematologica 95 8 1308 16 20534700 10.3324/haematol.2009. 016824 1:CAS:528:DC%2BC3cXhtlShu7jJ
46. Greenberg PL, Rigsby CK, Stone RM, et al. NCCN Task Force Report: Transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2009;7(Suppl 9).
47. N Gattermann 2008 Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload Int J Hematol 88 24 9 18581200 10.1007/s12185-008-0118-z
48. M Schmid 2009 Iron chelation therapy in MDS: what have we learnt recently? Blood Rev 23 Suppl 1 S21 5 20116636 10.1016/S0268-960X(09)70006-2 1:CAS:528:DC%2BC3cXjtlGksLY%3D
49. JM Bennett MDS Foundation's Working Group on Transfusional Iron Overload 2008 Consensus statement on iron overload in myelodysplastic syndromes Am J Hematol 83 858 61 18767130 10.1002/ajh.21269 This is one of several "expert-opinion" practical guidelines on the management of iron overload in patients with MDS, but it is limited by the lack of a solid evidence base on which to base recommendations